Jennifer Phipps
EVP & CFO at BrightSpring Health Services
As a reminder, net interest expense includes interest income related to cash flow hedges due to our three received variable pay fixed interest rate swap agreements that we have in place, set to mature on 09/30/2025. As part of our process to monitor and address risk, during the first quarter we entered into an extension of our interest rate hedge, providing stability to our interest rate risk through September 2026. Prior to any proceeds from the pending community living divestiture, quarterly interest expense is still expected to be approximately $43,000,000 per quarter, including approximately $1,200,000 of interest expense related to the TEU instrument. Turning to our guidance for 2025, we are increasing our expectations for total revenue and adjusted EBITDA that was provided in March, which excludes the Community Living business. Total revenue is expected to be in the range of $12,200,000,000 to $12,600,000,000 including pharmacy solutions revenue of $10,750,000,000 to $11,100,000,000 and provider services revenue of 1,450,000,000 to $1,500,000,000 This revenue range reflects 21.1% to 25.1% growth over full year 2024, excluding community living in both years.